Ozette Technologies
Ozette is an AI-driven platform that provides faster biological insights from cytometry data. It aims to eliminate the labor-intensive and time-consuming nature of current cytometry solutions by offering a cloud-native analysis platform paired with in-house data science and translational science expertise. The platform transforms raw flow cytometry immune data into comprehensive, annotated cell populations, enabling the discovery of rare or uncharacterized phenotypes. Ozette's technology facilitates advancements in drug development, particularly in immuno-oncology, by uncovering distinct cell populations that influence immune effectiveness. Their approach combines human expertise with computational methods, offering a higher resolution, depth, and biological relevance compared to traditional clustering programs. Ozette supports both spectral and conventional cytometry data and is expanding to include single-cell CITE-seq data for integrative analyses.
Ozette Technologies
Ozette is an AI-driven platform that provides faster biological insights from cytometry data. It aims to eliminate the labor-intensive and time-consuming nature of current cytometry solutions by offering a cloud-native analysis platform paired with in-house data science and translational science expertise. The platform transforms raw flow cytometry immune data into comprehensive, annotated cell populations, enabling the discovery of rare or uncharacterized phenotypes. Ozette's technology facilitates advancements in drug development, particularly in immuno-oncology, by uncovering distinct cell populations that influence immune effectiveness. Their approach combines human expertise with computational methods, offering a higher resolution, depth, and biological relevance compared to traditional clustering programs. Ozette supports both spectral and conventional cytometry data and is expanding to include single-cell CITE-seq data for integrative analyses.
TL;DR
Headquarters: Seattle, Washington
Core product: Resolve — cloud-native adaptive unmixing for spectral cytometry
Focus: AI-driven computational analysis of high-dimensional immune single-cell data
Founded: 2020
Recent disclosed funding: $32,000,000 total (including a July 2022 round)
Company Overview
Problem Domain
Labor-intensive, low-resolution analysis of cytometry/single-cell immune data that slows discovery in drug development and diagnostics.
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
$6,000,000
Seed funding announced to develop AI-powered immune monitoring platform.
$26,000,000
Reported July 2022 round; investors reported across sources include Cercano Management, M12, Madrona Venture Group, Alexandria Venture Investments, OCV Partners, and Duke University.
Investor Signal
“Cercano Management; M12 (Microsoft's venture fund); Madrona Venture Group; Alexandria Venture Investments; OCV Partners; Duke University”